Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Latest Information Update: 22 Nov 2023
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- Acronyms ENDURANCE
- 17 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 30 Nov 2025.
- 05 Mar 2022 Results of a pooled analysis (from SWOG S0777, ENDURANCE, MAIA, and ALCYONE) to the compare the efficacy of relevant therapies for the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma published in the Advances in Therapy
- 14 Dec 2021 Results of post-hoc analysis presented at the 63rd American Society of Hematology Annual Meeting and Exposition.